Rifaximin CAS: 80621-81-4
MF: C43H51N3O11
MW: 785.88

Rifaximin (CAS 80621-81-4)

Rifaximin | CAS 80621-81-4 is rated 5.0 out of 5 by 1.
  • y_2021, m_11, d_25, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.20
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_205841, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 86ms
  • REVIEWS, PRODUCT
loading
5
1
4
0
3
0
2
0
1
0
Alternate Names: Rifaximin is also known as Rifacol.
Application: Rifaximin is a Pregnane X receptor agonist and antibiotic that inhibits RNA synthesis and activates PXR.
CAS Number: 80621-81-4
Purity: ≥99%
Molecular Weight: 785.88
Molecular Formula: C43H51N3O11
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits
loading

Rifaximin is an antibiotic that inhibits RNA synthesis and acts as a PXR (pregnane-X-receptor) activator. Rifaximin is a derivative of rifamycin that has been shown to act strongly against Enterococcus, Streptococcus and Staphylococcus, with less activity against Enterobacteriaceae. Rifaximin has been used in a variety of gastrointestinal and intestinal epithelial cell studies. Rifaximin reduced the number of colon tumors and suppressed expression of TNFα and Il-1β induced in a colon cancer, PXR-humanized mouse model.


References

1. Gillis, J.C. and Brogden, R.N. 1995. Drugs. 49: 467-484. PMID: 7774516

2. Mencarelli, A., et al. 2010. Biochem Pharmacol. [Epub ahead of print]. PMID: 20816942

3. Cottreau, J., et al. 2010. Expert Rev Anti Infect Ther. 8: 747-760. PMID: 20586560

4. Cheng, J., et al. 2010. J. Pharmacol. Exp. Ther. 335: 32-41. PMID: 20627999

Physical State :
Solid
Solubility :
Soluble in DMSO (47 mg/ml), water (<1 mg/ml), ethanol (157 mg/ml), alcohols, and chloroform.
Storage :
Store at 4° C
Melting Point :
218-228° C
Refractive Index :
n20D 1.63 (Predicted)
IC50 :
Staphylococcus epidermidis RNA polymerase mediated transcription: IC50 = 89.07 nM; PXR: EC5050 = 2.2 µM (human)
pK Values :
pKa: 8.06 (Predicted), pKb: 4.42 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
2
RTECS :
KD1576000
PubChem CID :
Merck Index :
14: 8220
MDL Number :
MFCD00864973
SMILES :
C[[email protected]]1/C=C/C=C(\\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[[email protected]@](C4=O)(O/C=C/[[email protected]@H]([[email protected]]([[email protected]]([[email protected]@H]([[email protected]@H]([[email protected]@H]([[email protected]]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)/C

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Rifaximin (CAS 80621-81-4)  Product Citations

See how others have used Rifaximin (CAS 80621-81-4). Click on the entry to view the PubMed entry .

Citations 1 to 1 of 1 total

PMID: # 32760742  Front Vet Sci. 344.

Citations 1 to 1 of 1 total

Hi, we bought the batch F1715 of sc-205841B. I'd like to know if the purity was measured on dried basis. Morover I noticed that the result of loss on dry is pretty low (&lt;0.15%) we found only rifaximin with water content above 3%, how do you keep it low?

Asked by: A Perandini
Thank you for your question. It would be helpful if you could call us, allowing for a more interactive discussion of this and other related questions.
Answered by: Technical Support
Date published: 2021-07-23
  • y_2021, m_11, d_26, h_18CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.20
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_205841, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 116ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Cheng et al Cheng et al. (PubMed ID 20627999) found that rifaximin showed a therapeutic effect against inflammatory bowel disease via human PXR-mediated inhibition of the NF- B signaling cascade. -SCBT Publication Review
Date published: 2015-03-09
  • y_2021, m_11, d_25, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.20
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_205841, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 7ms
  • REVIEWS, PRODUCT